DaVita HealthCare Partners Inc. (NYSE:DVA) – Equities research analysts at Jefferies Group lowered their FY2017 earnings per share (EPS) estimates for DaVita HealthCare Partners in a research note issued to investors on Monday. Jefferies Group analyst C. Cooper now anticipates that the company will post earnings of $3.34 per share for the year, down from their prior forecast of $3.72. Jefferies Group has a “Hold” rating and a $70.00 price target on the stock. Jefferies Group also issued estimates for DaVita HealthCare Partners’ FY2018 earnings at $3.53 EPS and FY2019 earnings at $4.00 EPS.

DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by $0.03. The company had revenue of $3.70 billion for the quarter, compared to analysts’ expectations of $3.69 billion. DaVita HealthCare Partners had a return on equity of 14.85% and a net margin of 8.28%.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/06/28/brokers-set-expectations-for-davita-healthcare-partners-inc-s-fy2017-earnings-dva.html.

DVA has been the topic of several other research reports. TheStreet upgraded shares of DaVita HealthCare Partners from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research note on Tuesday, April 18th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $62.00 price target on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $69.50.

Shares of DaVita HealthCare Partners (NYSE:DVA) opened at 64.12 on Wednesday. The stock has a market cap of $12.48 billion, a P/E ratio of 10.53 and a beta of 1.00. DaVita HealthCare Partners has a 52-week low of $54.50 and a 52-week high of $78.77. The firm’s 50 day moving average price is $65.51 and its 200 day moving average price is $66.12.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVA. National Pension Service boosted its position in DaVita HealthCare Partners by 6.2% in the first quarter. National Pension Service now owns 155,161 shares of the company’s stock worth $10,629,000 after buying an additional 9,075 shares during the period. Gulf International Bank UK Ltd boosted its position in DaVita HealthCare Partners by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 50,891 shares of the company’s stock worth $3,459,000 after buying an additional 700 shares during the period. Creative Planning boosted its position in DaVita HealthCare Partners by 132.9% in the first quarter. Creative Planning now owns 10,725 shares of the company’s stock worth $729,000 after buying an additional 6,120 shares during the period. Raymond James Trust N.A. purchased a new position in DaVita HealthCare Partners during the first quarter worth $202,000. Finally, Chevy Chase Trust Holdings Inc. boosted its position in DaVita HealthCare Partners by 1.7% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 134,325 shares of the company’s stock worth $9,130,000 after buying an additional 2,246 shares during the period. Institutional investors own 82.46% of the company’s stock.

In related news, Director William L. Roper sold 12,994 shares of DaVita HealthCare Partners stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $65.89, for a total transaction of $856,174.66. Following the transaction, the director now owns 45,277 shares in the company, valued at approximately $2,983,301.53. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Javier Rodriguez sold 1,294 shares of DaVita HealthCare Partners stock in a transaction on Monday, May 15th. The shares were sold at an average price of $66.21, for a total transaction of $85,675.74. Following the transaction, the chief executive officer now owns 99,111 shares in the company, valued at approximately $6,562,139.31. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,702 shares of company stock worth $1,495,492. 2.00% of the stock is owned by corporate insiders.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Earnings History and Estimates for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.